Hyperphosphatemia Treatment Market Size, Share, Opportunities, And Trends By Product (Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate, Others), By Test Type (Low Serum Calcium Level Test, Blood Urea Nitrogen Test, Phosphate Level Test, Creatinine Value Test), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores), And By Geography - Forecasts From 2023 To 2028

The hyperphosphatemia treatment market is estimated to grow at a CAGR of 6.59% during the forecast period.

Hyperphosphatemia is a disorder when the body's phosphate levels are extremely low. Other factors that contribute to hyperphosphatemia include uncontrolled diabetes, excessive vitamin D levels, diabetic ketoacidosis, and low parathyroid hormone levels.

Opportunities for the hyperphosphatemia treatment market to increase

The incidence of chronic illnesses is rising, as is the number of elderly people, which are two key reasons for the hyperphosphatemia treatment market growth. However, the FDA's strict rules and the rise in pharmacological adverse effects for treating hyperphosphatemia might restrain market expansion. In addition, the market is anticipated to benefit financially from the tremendous potential of emerging economies like Brazil, South Africa, China, India, and others that have not yet reached their full potential.

An increasing number of people on dialysis

One of the main reasons driving the hyperphosphatemia treatment market growth is the rise in chronic renal diseases on a global scale. The prevalence of CKD is growing tremendously and will continue to increase in the future. According to data released by the American Kidney Fund, Americans with renal disease are 37 million. American citizens with renal failure number about 807,000. The prevalence of kidney illness is rising alarmingly. 15% of American adults are now affected, which amounts to more than 1 in 7. After a specific period, hyperphosphatemia was seen in the majority of dialysis patients. Thus, the rise in chronic renal illnesses is fueling the hyperphosphatemia treatment industry expansion.

Advancements in drug development

The advancement of research and treatment strategies is predicted to fuel the global hyperphosphatemia treatment market. For instance, it was discovered in 2022 that Lupin had released Sevelamer Hydrochloride pills (800 mg) in the USA, a drug intended to treat hyperphosphatemia in persons with chronic renal impairment. After gaining US FDA approval, the item had been made accessible. In contrast to those who got just tenapanor or only phosphate binders, maintenance dialysis patients with chronic renal failure who received a combination treatment of tenapanor and phosphate binders reported better control of hyperphosphatemia.

Increasing investments in research

The expansion of the hyperphosphatemia treatment industry is also expected to be aided by rising research funding for several rare disorders, including X-linked hypophosphatemia (XLH), and high healthcare costs. For instance, Genome Canada and the Canadian Institutes for Health Research worked together to research rare genetic diseases using Next-Generation Sequencing (NGS) technology. As a result, this factor has caused the hyperphosphatemia treatment market to expand dramatically.

Introduction of new hyperphosphatemia therapeutics by researchers

In CKD patients receiving dialysis, optimal phosphate management is exceedingly challenging to attain. Despite the amazing developments in dialysis treatments throughout the years, the capacity to manage phosphate levels in dialysis patients has not considerably improved. Additionally, phosphate binders have a variety of unfavourable side effects. In the future, non-phosphate binders like Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3), are anticipated to take the role of phosphate binders in the treatment of hyperphosphatemia, which will fuel the hyperphosphatemia treatment market growth.

Increasing utilization in hospitals

Most hospital patients with renal illnesses require the usage of hyperphosphatemia medications. Patients who are on dialysis or those with chronic renal failure. The blood phosphate levels of these patients have increased because they are unable to eliminate the surplus quantities of phosphorus as a result of their kidneys not functioning correctly and are at risk of developing hospital-acquired hyperphosphatemia.

Hyperphosphatemia was present in these cases. The serum phosphate levels are decreased using medications. A prolonged period of untreated hospital-acquired hyperphosphatemia might raise the risk of mortality from serious cardiovascular problems such as congestive heart failure and death from arrhythmias.

The market for treating hyperphosphatemia in North America is anticipated to expand quickly. 

North America is expected to have the highest hyperphosphatemia treatment market share because of the ageing population and a rise in chronic renal disease patients. Various product innovations in the region are also fueling the market. For instance, the biopharmaceutical business Ardelyx, Inc. has announced that three posters were exhibited during Kidney Week 2022, which was hosted in Orlando, Florida. The company was formed to identify, develop, and commercialize breakthrough first-in-class medicines to address large unmet medical needs. XPHOZAH (tenapanor) is a phosphate absorption inhibitor (PAI) created and discovered by Ardelyx for the treatment of chronic kidney disease (CKD) in dialysis patients.

Market Player Strategies

Since numerous businesses have begun to enter the hyperphosphatemia treatment industry as a result of technical improvements, the level of competition has increased. For instance, Shield Therapeutics wants to create drugs to treat anaemia caused by iron deficiency and hyperphosphatemia. Feraccru, a product of the firm, is its best-selling item. In addition, the business has unveiled PT30, which provides hypoallergenic IV iron treatment.

Market Key Developments

• In July 2023, Tenapanor's New Drug Application (NDA) was approved for assessment by China's National Medical Products Administration's Centre for Drug Evaluation for its ability to regulate serum phosphorus in adult patients with chronic renal disease and affect hemodynamics.
• In October 2022, Japanese Kyowa Kirin Co. Ltd. submitted a new medication application for the treatment of hyperphosphatemia in people with chronic kidney disease (CKD).
• In March 2022, the pharmaceutical company Lupin announced that it has begun selling Sevelamer Hydrochloride tablets (800 mg), which are intended to treat hyperphosphatemia in people with chronic renal disease.

Hyperphosphatemia Treatment Market Scope:

 

Report Metric	Details
Growth Rate	CAGR of 6.59% from 2021 to 2028
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Product, Test Type, Distribution Channel, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Kissei, SRIASS, Clarivate, Ardelyx, MIMS, Astellas Pharma, Cigna, Chugai Pharm, Mayo Clinic
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Product
  • Sevelamer
  • Calcium-based Phosphate Binders
  • Iron-based Phosphate Binders
  • Lanthanum Carbonate
  • Others
• By Test Type
  • Low Serum Calcium Level Test
  • Blood Urea Nitrogen Test
  • Phosphate Level Test
  • Creatinine Value Test
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. HYPERPHOSPHATEMIA TREATMENT MARKET, BY PRODUCT

5.1. Introduction

5.2. Sevelamer

5.3. Calcium-based Phosphate Binders

5.4. Iron-based Phosphate Binders

5.5. Lanthanum Carbonate

5.6. Others

6. HYPERPHOSPHATEMIA TREATMENT MARKET, BY TEST TYPE

6.1. Introduction

6.2. Low Serum Calcium Level Test

6.3. Blood Urea Nitrogen Test

6.4. Phosphate Level Test

6.5. Creatinine Value Test

7. HYPERPHOSPHATEMIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Online Stores

8. HYPERPHOSPHATEMIA TREATMENT MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Kissei

10.2. SRIASS

10.3. Clarivate

10.4. Ardelyx

10.5. MIMS

10.6. Astellas Pharma

10.7. Cigna

10.8. Chugai Pharm

10.9. Mayo Clinic

Kissei

SRIASS

Clarivate

Ardelyx

MIMS

Astellas Pharma

Cigna

Chugai Pharm

Mayo Clinic